1. Home
  2. SLDP vs TYRA Comparison

SLDP vs TYRA Comparison

Compare SLDP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$5.31

Market Cap

993.3M

Sector

Energy

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$21.65

Market Cap

844.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
TYRA
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
993.3M
844.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SLDP
TYRA
Price
$5.31
$21.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$31.20
AVG Volume (30 Days)
10.0M
496.7K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,802,000.00
N/A
Revenue This Year
$27.38
N/A
Revenue Next Year
$36.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.85
N/A
52 Week Low
$0.68
$6.42
52 Week High
$8.86
$22.83

Technical Indicators

Market Signals
Indicator
SLDP
TYRA
Relative Strength Index (RSI) 47.16 68.26
Support Level $4.78 $20.08
Resistance Level $5.33 $22.83
Average True Range (ATR) 0.37 1.61
MACD -0.04 0.12
Stochastic Oscillator 42.77 84.28

Price Performance

Historical Comparison
SLDP
TYRA

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: